Stryker's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Stryker in the second quarter 2026?
Stryker Corp achieved a return on average equity (ROE) of 16.36 % in its second quarter 2026, which is below Stryker's average return on equity, which stands at 16.82%.

ROE has advanced compared to 15.1% in the first quarter 2026, due to net income growth.

Within the Medical Equipment & Supplies industry 22 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 930, from total ROE ranking in the first quarter 2026 at 931.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	13.2 %	9.79 %	8.66 %	8.12 %	-
Y / Y Net Income Change	44.34 %	13.91 %	55.49 %	3 %	7.15 %
Net Income (TTM) in Millions	3,729	3,337	3,246	2,943	2,918
Return On Equity (TTM)	16.36 %	15.1 %	15.04 %	13.92 %	14.08 %
SYK's Total Ranking	# 930	# 931	# 602	# 704	# 663
Equity (TTM) in Millions	23,988	22,979	22,420	21,785	21,191
Seq. Equity Change	4.39 %	2.49 %	2.91 %	2.8 %	1.25 %
Seq. Net Income Change	71.28 %	-12.25 %	-1.16 %	-2.83 %	35.17 %

Back to SYK Management Effectiveness >> SYK's 5 Years Annual ROE >> Compare SYK ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 23
Sector	# 102
Overall	# 930

Return On Equity Statistics
High	Average	Low
35.29 %	16.82 %	5.84 %
(Dec 31 2018)		IV. Quarter

News about Stryker Corp Return on Equity ROE

Stryker Corporation Announces CFO Transition as Glenn Boehnlein Retires After 22 Years,

Stryker Corp Announces Leadership Transition as CFO Glenn Boehnlein Retires After 22 YearsStryker Corporation (NYSE: SYK) is set to embark on a new chapter as the company announces the retirement of Glenn S. Boehnlein from his role as Vice President and Chief Financial Officer (CFO). This significant leadership transition comes after an impressive 22-year tenure, during which Boehnlein played a crucial part in the organization s growth and success. Effective April 1, 2025, Preston Wells, currently serving as Group CFO for Stryker s Orthopaedics Group, will step into the role of Vice President, Chief Financial Officer.Boehnlein s decision to retire marks the end of an era for Stryker, a company renowned for its innovative medical technologies and strong market presence. Throughout his career, Boehnlein demonstrated exceptional financial oversight, strategic vision, and an unwavering commitment to the company’s core values. His stewardship has not only contributed to Stryker s financial health but has also helped shape the company into a global leader in the medical device industry.

SYK Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	22,420	20,634	18,593	16,616	14,877
Y / Y Equity Change	8.66 %	10.98 %	11.9 %	11.69 %	13.7 %
Net Income in Millions	3,246	2,993	3,165	2,358	1,994
Y / Y Net Income Change	8.45 %	-5.43 %	34.22 %	18.25 %	24.7 %
Return On Equity	14.48 %	14.51 %	17.02 %	14.19 %	13.4 %

Back to SYK Management Effectiveness >> SYK's 5 Years Annual ROE >> Compare SYK ROE to its Competitors

Annual Roe Comment

In 2025 ROE fell to 14.48 %, despite net income growth.

More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
SYK's' Return on Equity at Yahoo Finance
SYK's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SYK's Competitors
Subscribers only: Roe for Stryker's Suppliers
Subscribers only: Return On Equity for SYK's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Agilent Technologies inc	41.99 %
Eton Pharmaceuticals Inc	40.13 %
Adma Biologics Inc	39.59 %
Dexcom Inc	36.25 %
Transmedics Group Inc	33.37 %
Arcutis Biotherapeutics Inc	32.92 %
Caredx Inc	32.81 %
Zevra Therapeutics Inc	32.56 %
Acadia Pharmaceuticals Inc	32.39 %
Pro dex Inc	31.96 %
Protalix Biotherapeutics inc	31.61 %
Illumina Inc	31.08 %
Innoviva Inc	30.03 %
Phibro Animal Health Corporation	29.66 %
Chemed Corporation	29.45 %
Solventum Corporation	28.96 %
Pacs Group Inc	27.00 %
Sotera Health Company	26.75 %
Insulet Corporation	26.69 %
Bioventus Inc	25.96 %
Johnson and Johnson	25.74 %
Encompass Health Corporation	25.52 %
Resmed Inc	24.21 %
Healthcare Services Group Inc	24.12 %
Electromed Inc	23.65 %
Iradimed Corporation	23.45 %
Vertex Pharmaceuticals Inc	23.31 %
Lantheus Holdings Inc	23.27 %
Msa Safety Inc	23.15 %
Prestige Consumer Healthcare Inc	21.77 %

Date modified: 2026-09-26T07:00:27+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.